Rescuing a Failed Acute Myeloid Leukemia Drug (Troxatyl) using Biomarkers

CSEF · 2009 Pharmacology (Senior Division Only)

Overview

Objectives/Goals This project presents a method of using deoxycytidine kinase (DCK) biomarkers to improve the efficacy of a failed cancer drug, Troxatyl (TRO), in acute myeloid leukemia (AML) treatments through patient selection with genetic biomarkers. Methods/Materials Clinical data of TRO in AML patients were obtained from RSQ Pharmaceuticals under proprietary agreements. This study extracted all known 133 SNPs on the DCK gene region from three publicly accessible databases (NCBI, ENSEMBL, and GENECARDS). Correlations between patient clinical responses and genetic biomarkers were obtained by using SPSS software and modules developed by RSQ. Based on these correlations, two haplotypes were generated from two identified SNPs. Finally, a link between two haplotypes with gene expression was established, and the results were verified by clinical data (not included in this study). Results TRO treatment has a genetic predisposition factor related to different patients' responsiveness to the drug. A single SNP on DCK is not sufficient to predict the drug responsiveness in AML patients; however, two SNPs, namely TROAML1 (C/G) and TROAML2 (C/T), on DCK's 5'-UTR region form two unique haplotypes that are directly correlated to TRO efficacy. Conclusions/Discussion 50% of the heterozygous allele (C/G-C/T) patients (31.1% of total patients) and 100% of the minor homozygous allele (G/G-T/T) patients (2.5%) responded to TRO treatment. Thus, patients who have at least one allele of G-T will most likely respond to TRO treatment, because these patients produce higher amounts of dCK protein. This predicted G-T haplotype will cover 1/3 of all AML patients, and will increase the efficacy rate from 18% (the original efficacy rate) to 60%. A new clinical trial that selects patients using the aforementioned SNP biomarkers is needed for TRO to obtain FDA approval.

Summary statement

This project applied a method of using biomarkers to improve the efficacy of Troxatyl, a failed leukemia drug, in order to gain FDA approval.

Help received

Used software provided by RSQ Pharmaceuticals

Competition history

  • CSEF 2009 Pharmacology (Senior Division Only) · Entry S1811

Resources

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Browse more like this

Source: California Science & Engineering Fair public projects

Save projects to your library

Sign in with Google to keep track of projects you find interesting, organized into folders. An account also raises your daily allowance for “Has this been done?”, and lets you create a key for the MCP server with a much higher limit than anonymous use. Browsing stays public.

Continue with Google